On 4 May, ASLM’s LabCoP, in collaboration with EDCTP and TB-CAPT, convened an Extended ECHO session that focused on exploring advancements in the lipoarabinomannan (LAM) diagnostic development pipeline, approaches for clinical adoption in field settings, and strategies for quality assessment. The information in this session helps address the urgent need for TB tools and diagnostic techniques that can both detect the disease and identify strains that are resistant to available TB drugs and the World Health Organization’s recommendation to use urine-based lipoarabinomannan (LAM) antigen testing to aid in the diagnosis of active TB in HIV-infected adults, adolescents, and children. Presentations were made by Lesley Scott, Head, Research and Development, Wits Diagnostic Innovation Hub, University of the Witwatersrand, South Africa; Dr Jeremy Nel, Division of Infectious Diseases, Department of Internal Medicine, University of the Witwatersrand, South Africa; Anura David, Senior Medical Scientist, Wits Diagnostic Innovation Hub, University of the Witwatersrand, South Africa; and Morten Ruhwald, TB programme, FIND, Geneva. Please follow the links below to view the recorded ECHO session and download presentation slides.